Systemic sclerosis & Raynaud's
Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis
Authors' conclusion
Multiple biomarkers, especially VCAM-1, E-selectin, SP-D and CXCL4, provide prognostic utility beyond that of established risk factors for patients with SSc.
Study context
- Population
- Participants with systemic sclerosis (SSc) with sera, high-resolution CT and lung function within 12 months of baseline, Australian Scleroderma Cohort Study252 (61.9%) with SSc-ILD
- Participants
- 407 participants
- Outcome
- Mortality and ILD progression
Methodological detailsunivariable and multivariable analyses, Twenty-seven of the prespecified 28 serum biomarkers analysed
- Univariable and multivariable analyses
- Twenty-seven of the prespecified 28 serum biomarkers analysed
Main finding
As reported in the abstract
Mortality, high biomarker levels
- Biomarkers associated with increased mortality
- 16
- VCAM-1, HR
- 3.55 (95% CI 2.37-5.33; P < 0.001)
- SP-D, HR (1.57-3.31; P < 0.001)
- 2.28
- E-selectin, HR (1.53-3.14; P < 0.001)
- 2.19
- IL-6, HR (1.50-3.09; P < 0.001)
- 2.15
- MMP-3, HR (1.42-2.95; P < 0.001)
- 2.05
- ET-1, HR (1.40-2.92; P < 0.001)
- 2.03
- Biomarkers independently associated with mortality after adjustment for sex, age and baseline FVC%predicted
- 11
Observational data: associations, not effects.
Further findings
ILD progression · 1-year follow-up
- CXCL4, OR (1.46-4.88; P = 0.001)
- 2.67
- MMP-1, OR (1.43-4.59; P = 0.002)
- 2.56
- ET-1, OR (1.24-3.83; P = 0.007)
- 2.18
Original publication
Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Rheumatology (Oxford). Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →